61.87
전일 마감가:
$62.62
열려 있는:
$62.3
하루 거래량:
662.12K
Relative Volume:
0.47
시가총액:
$9.21B
수익:
-
순이익/손실:
$-946.53M
주가수익비율:
-8.8812
EPS:
-6.9664
순현금흐름:
$-814.94M
1주 성능:
+2.74%
1개월 성능:
+13.19%
6개월 성능:
+0.85%
1년 성능:
+91.61%
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PCVX
Vaxcyte Inc
|
61.87 | 9.13B | 0 | -946.53M | -814.94M | -6.9664 |
|
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재확인 | Needham | Buy |
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Odyssean, LLC's Vaxcyte Inc(PCVX) Holding History - GuruFocus
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research - MarketBeat
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline - DirectorsTalk Interviews
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock - Stock Titan
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
PCVX SWOT Analysis: Key Financial Insights Revealed in 10-Q Fili - GuruFocus
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares - marketbeat.com
Vaxcyte (PCVX) Advances Phase 3 Trials Amid Mixed Market Signals - GuruFocus
Vaxcyte, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock - MarketBeat
Vaxcyte Q2 net loss widens on higher expenses - TradingView
Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingView
PCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingView
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M - TradingView
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. SEC Filing (Aug 5, 2026) - Stock Titan
BRIEF-Vaxcyte Q2 Operating Expenses USD 302.777 Million - TradingView
Press Release: Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
PCVX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking The 101.55% Potential Upside - DirectorsTalk Interviews
PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale - Stock Titan
Current ratio of Vaxcyte, Inc. – XETR:5VA - TradingView
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Liquidity Mapping Around (PCVX) Price Events - Stock Traders Daily
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP - MarketBeat
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vaxcyte (PCVX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
백스사이트 주식 (PCVX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dhaliwal Harpreet S. | Chief Technical Ops Officer |
Aug 05 '26 |
Sale |
55.00 |
17,000 |
935,068 |
76,756 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Aug 03 '26 |
Option Exercise |
5.35 |
2,250 |
12,038 |
159,791 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Aug 03 '26 |
Sale |
53.86 |
2,250 |
121,195 |
157,541 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Aug 03 '26 |
Option Exercise |
5.35 |
10,000 |
53,500 |
115,176 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Aug 03 '26 |
Sale |
53.89 |
10,000 |
538,879 |
105,176 |
자본화:
|
볼륨(24시간):